Suppliers / Adare Pharmaceuticals

Adare Pharmaceuticals

Italy 8 employees Updated 9 July 2026

Adare Pharmaceuticals is an API manufacturer based in Italy. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its filings concentrate with DPM (TN), MPA (SE) and ARCSA (EC). Its GMP standing is certified by ANSM (FR), EMA and ANVISA (Brazil), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 25 February 2025 as VAI.

2
active US DMFs
0
valid CEPs
7
registered plants 2 with an FDA FEI number
12
filings across 7 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 25 February 2025 VAI US FDA
  • 28 October 2022 VAI US FDA
  • 25 January 2019 NAI US FDA
  • 11 July 2018 NAI US FDA
  • 13 April 2018 VAI US FDA
  • 19 May 2017 NAI US FDA
  • 24 February 2017 VAI US FDA
  • 30 May 2014 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
HOUDAN, France Not on file
PESSANO CON BORNAGO (MI), Italy Not on file
Pessano Con Bornago, Italy Not on file
San Giuliano Milanese, Italy Not on file
Pessano Con Bornago, Italy 1000573478
VANDALIA, United States Not on file

1 further sites are on record.

What they file, and where

Molecule Regulators Docs
Acetaminophen US FDA 1
Ibuprofen US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
DPM (TN) 2 None
MPA (SE) 2 None
ARCSA (EC) 2 None
US FDA 2 1
NMPA (CN) 2 None
MINSA (CR) 1 None
ANSM (FR) None 11
EMA None 7
ANVISA (Brazil) None 1

Comparing suppliers?

Choose your molecules and target markets. Adare Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 6 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 25 February 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates